Skip to main content
Top
Published in: Journal of Cardiovascular Magnetic Resonance 1/2013

Open Access 01-12-2013 | Research

Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function

Authors: Kan N Hor, Michael D Taylor, Hussein R Al-Khalidi, Linda H Cripe, Subha V Raman, John L Jefferies, Robert O’Donnell, D Woodrow Benson, Wojciech Mazur

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2013

Login to get access

Abstract

Background

Duchenne muscular dystrophy (DMD), an X-linked disorder affects approximately 1 in 5000 males, is universally associated with heart disease. We previously identified myocardial disease by late gadolinium enhancement (LGE) in DMD subjects at various stages of disease, but the true prevalence is unclear. Cardiovascular magnetic resonance (CMR) is well established for both assessment of ventricular function and myocardial fibrosis by LGE. We sought to establish i) prevalence and distribution of LGE in a large DMD population and ii) relationship among LGE, age, LVEF by CMR and current living status.

Methods

Current living status, demographic and CMR data including ventricular volumes, LVEF and LGE from 314 DMD patients undergoing evaluation at a single large tertiary referral center were analyzed.

Results

113 of 314 (36%) of DMD subjects showed LGE positivity with prevalence increasing from 17% of patients <10 years to 34% of those aged 10–15 years and 59% of those >15 years-old. Patients with LVEF ≥55% were LGE positive in 30% of cases; this increased to 84% for LVEF <55%. LGE was more prevalent in the free wall (531/1243, 42.7%) vs. septal segments (30/565, 5.3%). Patients with septal involvement were significantly older and had lower LVEF than those with isolated free wall LGE. Ten percent (11/113) patients who had LGE died 10.8 months after CMR. Only one patient from the LGE negative group died. Patients who died had higher heart rate, larger left ventricular volume and mass, greater number of positive LGE segment and increase incident of septal LGE compared to those who remained alive.

Conclusion

In DMD patients, LGE occurs early, is progressive and increases with both age and decreasing LVEF. Segmentally, the incidence of the number of positive LGE segments increase with age and lower LVEF. Older patients and those who died during the study period had more septal LGE involvement. The current studies suggest that the time course and distribution of LGE-positivity may be an important clinical biomarker to aid in the management of DMD-associated cardiac disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rodino-Klapac LR, Mendell JR, Sahenk Z: Update on the treatment of Duchenne muscular dystrophy. Curr. Neurol. Neurosci. Rep. 2013, 13 (3): 332-CrossRefPubMed Rodino-Klapac LR, Mendell JR, Sahenk Z: Update on the treatment of Duchenne muscular dystrophy. Curr. Neurol. Neurosci. Rep. 2013, 13 (3): 332-CrossRefPubMed
2.
3.
go back to reference Emery AE: Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul. Disord. 1991, 1 (1): 19-29. 10.1016/0960-8966(91)90039-U.CrossRefPubMed Emery AE: Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul. Disord. 1991, 1 (1): 19-29. 10.1016/0960-8966(91)90039-U.CrossRefPubMed
4.
go back to reference Hoffman EP, Brown RH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987, 51 (6): 919-28. 10.1016/0092-8674(87)90579-4.CrossRefPubMed Hoffman EP, Brown RH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987, 51 (6): 919-28. 10.1016/0092-8674(87)90579-4.CrossRefPubMed
5.
go back to reference Fischmann A, et al: Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J. Neurol. 2012, 260 (4): 969-74.CrossRefPubMed Fischmann A, et al: Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J. Neurol. 2012, 260 (4): 969-74.CrossRefPubMed
6.
go back to reference Vuillerot C, et al: Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure. Dev. Med. Child Neurol. 2010, 52 (1): 60-5. 10.1111/j.1469-8749.2009.03316.x.CrossRefPubMed Vuillerot C, et al: Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the motor function measure. Dev. Med. Child Neurol. 2010, 52 (1): 60-5. 10.1111/j.1469-8749.2009.03316.x.CrossRefPubMed
7.
go back to reference Bushby K, et al: Report on the 124th ENMC International workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2–4 April 2004, Naarden, The Netherlands. Neuromuscul. Disord. 2004, 14 (8–9): 526-34.CrossRefPubMed Bushby K, et al: Report on the 124th ENMC International workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2–4 April 2004, Naarden, The Netherlands. Neuromuscul. Disord. 2004, 14 (8–9): 526-34.CrossRefPubMed
8.
go back to reference Eagle M, et al: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilaton. Neuromuscul. Disord. 2002, 12: 926-9. 10.1016/S0960-8966(02)00140-2.CrossRefPubMed Eagle M, et al: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilaton. Neuromuscul. Disord. 2002, 12: 926-9. 10.1016/S0960-8966(02)00140-2.CrossRefPubMed
9.
go back to reference Abbott D, Carpenter J, Bushby K: Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Neuromuscul. Disord. 2012, 22 (5): 445-6. 10.1016/j.nmd.2012.02.004.CrossRefPubMed Abbott D, Carpenter J, Bushby K: Transition to adulthood for young men with Duchenne muscular dystrophy: research from the UK. Neuromuscul. Disord. 2012, 22 (5): 445-6. 10.1016/j.nmd.2012.02.004.CrossRefPubMed
10.
go back to reference Bushby K, et al: Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010, 9 (2): 177-89. 10.1016/S1474-4422(09)70272-8.CrossRefPubMed Bushby K, et al: Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010, 9 (2): 177-89. 10.1016/S1474-4422(09)70272-8.CrossRefPubMed
11.
go back to reference Bushby K, et al: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9 (1): 77-93. 10.1016/S1474-4422(09)70271-6.CrossRefPubMed Bushby K, et al: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9 (1): 77-93. 10.1016/S1474-4422(09)70271-6.CrossRefPubMed
12.
go back to reference Markham LW, Spicer RL, Cripe LH: The heart in muscular dystrophy. Pediatr. Ann. 2005, 34 (7): 531-5.CrossRefPubMed Markham LW, Spicer RL, Cripe LH: The heart in muscular dystrophy. Pediatr. Ann. 2005, 34 (7): 531-5.CrossRefPubMed
13.
go back to reference Schram G, et al: All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 2013, 61 (9): 948-54. 10.1016/j.jacc.2012.12.008.CrossRefPubMed Schram G, et al: All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 2013, 61 (9): 948-54. 10.1016/j.jacc.2012.12.008.CrossRefPubMed
14.
go back to reference Mazur W, et al: Patterns of left ventricular remodeling in patients with Duchenne muscular dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. Int. J. Cardiovasc. Imaging. 2012, 28 (1): 99-107. 10.1007/s10554-010-9781-2.CrossRefPubMed Mazur W, et al: Patterns of left ventricular remodeling in patients with Duchenne muscular dystrophy: a cardiac MRI study of ventricular geometry, global function, and strain. Int. J. Cardiovasc. Imaging. 2012, 28 (1): 99-107. 10.1007/s10554-010-9781-2.CrossRefPubMed
15.
go back to reference Moriuchi T, et al: Autopsy analyses of the muscular dystrophies. Tokushima J. Exp. Med. 1993, 40 (1–2): 83-93.PubMed Moriuchi T, et al: Autopsy analyses of the muscular dystrophies. Tokushima J. Exp. Med. 1993, 40 (1–2): 83-93.PubMed
16.
go back to reference Perloff JK, Henze E, Schelbert HR: Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation. 1984, 69 (1): 33-42. 10.1161/01.CIR.69.1.33.CrossRefPubMed Perloff JK, Henze E, Schelbert HR: Alterations in regional myocardial metabolism, perfusion, and wall motion in Duchenne muscular dystrophy studied by radionuclide imaging. Circulation. 1984, 69 (1): 33-42. 10.1161/01.CIR.69.1.33.CrossRefPubMed
17.
go back to reference Frankel K, Rosser R: The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum. Pathol. 1976, 7: 375-86. 10.1016/S0046-8177(76)80053-6.CrossRefPubMed Frankel K, Rosser R: The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum. Pathol. 1976, 7: 375-86. 10.1016/S0046-8177(76)80053-6.CrossRefPubMed
18.
go back to reference Silva MC, et al: Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J. Am. Coll. Cardiol. 2007, 49 (18): 1874-9. 10.1016/j.jacc.2006.10.078.CrossRefPubMed Silva MC, et al: Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J. Am. Coll. Cardiol. 2007, 49 (18): 1874-9. 10.1016/j.jacc.2006.10.078.CrossRefPubMed
19.
go back to reference Puchalski MD, et al: Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?. Int. J. Cardiovasc. Imaging. 2009, 25 (1): 57-63. 10.1007/s10554-008-9352-y.PubMedCentralCrossRefPubMed Puchalski MD, et al: Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne muscular dystrophy?. Int. J. Cardiovasc. Imaging. 2009, 25 (1): 57-63. 10.1007/s10554-008-9352-y.PubMedCentralCrossRefPubMed
20.
go back to reference van der Geest RJ, et al: Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. J. Comput. Assist. Tomogr. 1997, 21 (5): 756-65. 10.1097/00004728-199709000-00019.CrossRefPubMed van der Geest RJ, et al: Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. J. Comput. Assist. Tomogr. 1997, 21 (5): 756-65. 10.1097/00004728-199709000-00019.CrossRefPubMed
21.
go back to reference van der Geest RJ, Reiber JH: Quantification in cardiac MRI. J. Magn. Reson. Imaging. 1999, 10 (5): 602-8. 10.1002/(SICI)1522-2586(199911)10:5<602::AID-JMRI3>3.0.CO;2-C.CrossRefPubMed van der Geest RJ, Reiber JH: Quantification in cardiac MRI. J. Magn. Reson. Imaging. 1999, 10 (5): 602-8. 10.1002/(SICI)1522-2586(199911)10:5<602::AID-JMRI3>3.0.CO;2-C.CrossRefPubMed
22.
go back to reference Kim RJ, et al: Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999, 100 (19): 1992-2002. 10.1161/01.CIR.100.19.1992.CrossRefPubMed Kim RJ, et al: Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999, 100 (19): 1992-2002. 10.1161/01.CIR.100.19.1992.CrossRefPubMed
23.
go back to reference Kim RJ, et al: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N. Engl. J. Med. 2000, 343 (20): 1445-53. 10.1056/NEJM200011163432003.CrossRefPubMed Kim RJ, et al: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N. Engl. J. Med. 2000, 343 (20): 1445-53. 10.1056/NEJM200011163432003.CrossRefPubMed
24.
go back to reference Cerqueira MD, et al: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int. J. Cardiovasc. Imaging. 2002, 18 (1): 539-42.PubMed Cerqueira MD, et al: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int. J. Cardiovasc. Imaging. 2002, 18 (1): 539-42.PubMed
25.
go back to reference Herrmann S, et al: Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J. Am. Coll. Cardiol. 2011, 58 (4): 402-12. 10.1016/j.jacc.2011.02.059.CrossRefPubMed Herrmann S, et al: Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J. Am. Coll. Cardiol. 2011, 58 (4): 402-12. 10.1016/j.jacc.2011.02.059.CrossRefPubMed
26.
go back to reference Dweck MR, et al: Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J. Am. Coll. Cardiol. 2011, 58 (12): 1271-9. 10.1016/j.jacc.2011.03.064.CrossRefPubMed Dweck MR, et al: Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J. Am. Coll. Cardiol. 2011, 58 (12): 1271-9. 10.1016/j.jacc.2011.03.064.CrossRefPubMed
27.
go back to reference Ho CY, et al: Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N. Engl. J. Med. 2010, 363 (6): 552-63. 10.1056/NEJMoa1002659.PubMedCentralCrossRefPubMed Ho CY, et al: Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N. Engl. J. Med. 2010, 363 (6): 552-63. 10.1056/NEJMoa1002659.PubMedCentralCrossRefPubMed
28.
go back to reference O’Hanlon R, et al: Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56 (11): 867-74. 10.1016/j.jacc.2010.05.010.CrossRefPubMed O’Hanlon R, et al: Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56 (11): 867-74. 10.1016/j.jacc.2010.05.010.CrossRefPubMed
29.
go back to reference Wu KC, et al: Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998, 97 (8): 765-72. 10.1161/01.CIR.97.8.765.CrossRefPubMed Wu KC, et al: Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998, 97 (8): 765-72. 10.1161/01.CIR.97.8.765.CrossRefPubMed
30.
go back to reference Bruder O, et al: Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56 (11): 875-87. 10.1016/j.jacc.2010.05.007.CrossRefPubMed Bruder O, et al: Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010, 56 (11): 875-87. 10.1016/j.jacc.2010.05.007.CrossRefPubMed
31.
go back to reference Wu KC, et al: Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 2008, 51 (25): 2414-21. 10.1016/j.jacc.2008.03.018.PubMedCentralCrossRefPubMed Wu KC, et al: Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 2008, 51 (25): 2414-21. 10.1016/j.jacc.2008.03.018.PubMedCentralCrossRefPubMed
32.
go back to reference Assomull RG, et al: Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48 (10): 1977-85. 10.1016/j.jacc.2006.07.049.CrossRefPubMed Assomull RG, et al: Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48 (10): 1977-85. 10.1016/j.jacc.2006.07.049.CrossRefPubMed
33.
go back to reference Azevedo CF, et al: Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. Cardiol. 2010, 56 (4): 278-87. 10.1016/j.jacc.2009.12.074.CrossRefPubMed Azevedo CF, et al: Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. Cardiol. 2010, 56 (4): 278-87. 10.1016/j.jacc.2009.12.074.CrossRefPubMed
34.
go back to reference Walcher T, et al: Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Eur. J. Radiol. 2011, 80 (1): 115-9. 10.1016/j.ejrad.2010.07.005.CrossRefPubMed Walcher T, et al: Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Eur. J. Radiol. 2011, 80 (1): 115-9. 10.1016/j.ejrad.2010.07.005.CrossRefPubMed
35.
go back to reference Bilchick KC, et al: Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy. J. Cardiovasc. Magn. Reson. 2011, 13: 20-10.1186/1532-429X-13-20.PubMedCentralCrossRefPubMed Bilchick KC, et al: Prevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy. J. Cardiovasc. Magn. Reson. 2011, 13: 20-10.1186/1532-429X-13-20.PubMedCentralCrossRefPubMed
36.
go back to reference Bilchick KC, et al: Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc. Imaging. 2008, 1 (5): 561-8. 10.1016/j.jcmg.2008.04.013.PubMedCentralCrossRefPubMed Bilchick KC, et al: Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc. Imaging. 2008, 1 (5): 561-8. 10.1016/j.jcmg.2008.04.013.PubMedCentralCrossRefPubMed
37.
go back to reference Fong PY, et al: Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science. 1990, 250 (4981): 673-6. 10.1126/science.2173137.CrossRefPubMed Fong PY, et al: Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science. 1990, 250 (4981): 673-6. 10.1126/science.2173137.CrossRefPubMed
38.
go back to reference Rando TA: Oxidative stress and the pathogenesis of muscular dystrophies. Am. J. Phys. Med. Rehabil. 2002, 81 (11 Suppl): S175-86.CrossRefPubMed Rando TA: Oxidative stress and the pathogenesis of muscular dystrophies. Am. J. Phys. Med. Rehabil. 2002, 81 (11 Suppl): S175-86.CrossRefPubMed
39.
go back to reference Parsons SA, et al: Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J. Biol. Chem. 2007, 282 (13): 10068-78. 10.1074/jbc.M609368200.PubMedCentralCrossRefPubMed Parsons SA, et al: Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J. Biol. Chem. 2007, 282 (13): 10068-78. 10.1074/jbc.M609368200.PubMedCentralCrossRefPubMed
40.
go back to reference Mavrogeni S, et al: Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol. 2010, 10: 33-10.1186/1471-2377-10-33.PubMedCentralCrossRefPubMed Mavrogeni S, et al: Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol. 2010, 10: 33-10.1186/1471-2377-10-33.PubMedCentralCrossRefPubMed
41.
go back to reference Mavrogeni S, Papavassiliou A, Cokkinos DV: Myocarditis in a patient with Duchenne muscular dystrophy detected by cardiovascular magnetic resonance and cardiac biopsy. Int. J. Cardiol. 2009, 132 (3): e123-4. 10.1016/j.ijcard.2007.10.015.CrossRefPubMed Mavrogeni S, Papavassiliou A, Cokkinos DV: Myocarditis in a patient with Duchenne muscular dystrophy detected by cardiovascular magnetic resonance and cardiac biopsy. Int. J. Cardiol. 2009, 132 (3): e123-4. 10.1016/j.ijcard.2007.10.015.CrossRefPubMed
42.
go back to reference Wansapura JP, et al: Left ventricular T2 distribution in Duchenne muscular dystrophy. J. Cardiovasc. Magn. Reson. 2010, 12 (1): 14-10.1186/1532-429X-12-14.PubMedCentralCrossRefPubMed Wansapura JP, et al: Left ventricular T2 distribution in Duchenne muscular dystrophy. J. Cardiovasc. Magn. Reson. 2010, 12 (1): 14-10.1186/1532-429X-12-14.PubMedCentralCrossRefPubMed
43.
go back to reference Rafael-Fortney JA, et al: Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. Circulation. 2011, 124 (5): 582-8. 10.1161/CIRCULATIONAHA.111.031716.PubMedCentralCrossRefPubMed Rafael-Fortney JA, et al: Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice. Circulation. 2011, 124 (5): 582-8. 10.1161/CIRCULATIONAHA.111.031716.PubMedCentralCrossRefPubMed
44.
go back to reference Iles L, et al: Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 2008, 52 (19): 1574-80. 10.1016/j.jacc.2008.06.049.CrossRefPubMed Iles L, et al: Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 2008, 52 (19): 1574-80. 10.1016/j.jacc.2008.06.049.CrossRefPubMed
45.
go back to reference Jefferies JL, et al: Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005, 112 (18): 2799-804. 10.1161/CIRCULATIONAHA.104.528281.CrossRefPubMed Jefferies JL, et al: Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005, 112 (18): 2799-804. 10.1161/CIRCULATIONAHA.104.528281.CrossRefPubMed
46.
go back to reference Li JS, et al: The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose–response study. J. Pediatr. 2010, 157 (2): 282-7. 10.1016/j.jpeds.2010.02.042.CrossRefPubMed Li JS, et al: The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose–response study. J. Pediatr. 2010, 157 (2): 282-7. 10.1016/j.jpeds.2010.02.042.CrossRefPubMed
47.
go back to reference Rossignol P, et al: Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J. Am. Coll. Cardiol. 2011, 58 (19): 1958-66. 10.1016/j.jacc.2011.04.049.CrossRefPubMed Rossignol P, et al: Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J. Am. Coll. Cardiol. 2011, 58 (19): 1958-66. 10.1016/j.jacc.2011.04.049.CrossRefPubMed
Metadata
Title
Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function
Authors
Kan N Hor
Michael D Taylor
Hussein R Al-Khalidi
Linda H Cripe
Subha V Raman
John L Jefferies
Robert O’Donnell
D Woodrow Benson
Wojciech Mazur
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Cardiovascular Magnetic Resonance / Issue 1/2013
Electronic ISSN: 1532-429X
DOI
https://doi.org/10.1186/1532-429X-15-107

Other articles of this Issue 1/2013

Journal of Cardiovascular Magnetic Resonance 1/2013 Go to the issue